JP2023505192A5 - - Google Patents
Info
- Publication number
- JP2023505192A5 JP2023505192A5 JP2022533347A JP2022533347A JP2023505192A5 JP 2023505192 A5 JP2023505192 A5 JP 2023505192A5 JP 2022533347 A JP2022533347 A JP 2022533347A JP 2022533347 A JP2022533347 A JP 2022533347A JP 2023505192 A5 JP2023505192 A5 JP 2023505192A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- genetically modified
- dnt
- population
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944634P | 2019-12-06 | 2019-12-06 | |
| US62/944,634 | 2019-12-06 | ||
| PCT/CA2020/051682 WO2021108926A1 (en) | 2019-12-06 | 2020-12-07 | Genetically engineered double negative t cells as an adoptive cellular therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023505192A JP2023505192A (ja) | 2023-02-08 |
| JP2023505192A5 true JP2023505192A5 (https=) | 2023-12-11 |
Family
ID=76221295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533347A Pending JP2023505192A (ja) | 2019-12-06 | 2020-12-07 | 養子細胞療法としての遺伝子操作された二重陰性ｔ細胞 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230011889A1 (https=) |
| EP (1) | EP4069831A4 (https=) |
| JP (1) | JP2023505192A (https=) |
| CN (1) | CN114929865A (https=) |
| CA (1) | CA3160422A1 (https=) |
| WO (1) | WO2021108926A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113528449A (zh) * | 2020-04-20 | 2021-10-22 | 浙江瑞加美生物科技有限公司 | 一种制备通用型人源化car19-dnt细胞的技术及其应用 |
| EP4458378A4 (en) * | 2021-12-30 | 2025-07-09 | Chongqing Prec Biotech Co Ltd | TECHNIQUE FOR PREPARING A UNIVERSAL CAR-T CELL, AND APPLICATION OF A UNIVERSAL CAR-T CELL |
| WO2025106552A1 (en) * | 2023-11-14 | 2025-05-22 | Nkarta, Inc. | Methods and compositions for treatment of leukemia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10350243B2 (en) * | 2008-01-30 | 2019-07-16 | Memorial Sloan-Kettering Cancer Center | Methods for off-the-shelf-tumor immunotherapy using allogeneic T-cell precursors |
| WO2009097140A1 (en) * | 2008-01-30 | 2009-08-06 | Memorial Sloan-Kettering Cancer Center | Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors |
| CN104789595A (zh) * | 2015-04-20 | 2015-07-22 | 范国煌 | 嵌合抗原受体双阴性t细胞的构建方法 |
| CN107828730B (zh) * | 2017-11-07 | 2019-04-30 | 南京北恒生物科技有限公司 | 具有抗体药物抗性的通用型cart/tcrt细胞及其构建方法 |
-
2020
- 2020-12-07 WO PCT/CA2020/051682 patent/WO2021108926A1/en not_active Ceased
- 2020-12-07 EP EP20896982.4A patent/EP4069831A4/en active Pending
- 2020-12-07 JP JP2022533347A patent/JP2023505192A/ja active Pending
- 2020-12-07 US US17/782,071 patent/US20230011889A1/en active Pending
- 2020-12-07 CN CN202080091459.0A patent/CN114929865A/zh active Pending
- 2020-12-07 CA CA3160422A patent/CA3160422A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dagar et al. | Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments | |
| Sheykhhasan et al. | Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study | |
| Chu et al. | CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma | |
| Cerrano et al. | The advent of CAR T-cell therapy for lymphoproliferative neoplasms: integrating research into clinical practice | |
| EP4056588B1 (en) | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell | |
| Fesnak et al. | Engineered T cells: the promise and challenges of cancer immunotherapy | |
| JP2025013518A (ja) | Ｃａｒの抗腫瘍活性のための毒性管理 | |
| Schuberth et al. | Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma | |
| Park et al. | Interleukin-21 increases direct cytotoxicity and IFN-γ production of ex vivo expanded NK cells towards breast cancer cells | |
| García-Guerrero et al. | Overcoming chimeric antigen receptor (CAR) modified T-cell therapy limitations in multiple myeloma | |
| Wang et al. | Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy | |
| JP2023505192A5 (https=) | ||
| CN117959417A (zh) | 嵌合抗原受体和pd-1抑制剂的组合疗法 | |
| WO2016134284A1 (en) | Chimeric antigen receptors and uses thereof | |
| Wu et al. | Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells | |
| US20240247070A1 (en) | Compositions and methods for t-cell and cytokine activation | |
| Roussel et al. | Acute myeloid leukemia: from biology to clinical practices through development and pre-clinical therapeutics | |
| Cruz-Ramos et al. | CAR-T cell and Personalized Medicine | |
| Fang et al. | Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells | |
| Snauwaert et al. | Can immunotherapy specifically target acute myeloid leukemic stem cells? | |
| Zhou et al. | Targeting GPRC5D for multiple myeloma therapy | |
| Perna et al. | Immune-based therapeutic interventions for acute myeloid leukemia | |
| Jindal et al. | Current status of chimeric antigen receptor T-cell therapy in multiple myeloma | |
| WO2022092277A1 (ja) | Ｃｘｃｌ１２受容体発現キメラ抗原受容体（ｃａｒ）－ｔ細胞 | |
| Amlot | The clinical and experimental use of monoclonal antibodies to the IL-2 receptor |